Literature DB >> 25355250

Serum sRAGE as a potential biomarker for pediatric bronchiolitis: a pilot study.

Alberto García-Salido1, Gonzalo Oñoro, Gustavo J Melen, Vanesa Gómez-Piña, Ana Serrano-González, Manuel Ramírez-Orellana, Juan Casado-Flores.   

Abstract

PURPOSE: Traditional inflammatory biomarkers are insufficient for the evaluation of bronchiolitis severity. Recent investigations have shown that the receptor for advanced glycation end product (RAGE) and its soluble isoforms (sRAGE) play a critical role in the pathogenesis of lung injury. Main objective was to assess the serum levels of sRAGE of children with severe bronchiolitis admitted to the pediatric intensive care unit (PICU). Secondary objective was to study sRAGE correlation with the evolution and traditional biomarkers.
METHODS: Prospective, observational and descriptive study, 43 healthy controls and 37 patients (December 2011-February 2012) were enrolled. sRAGE levels were assessed and compared. In patients, the relation between sRAGE levels and clinical evolution, respiratory assistance, white blood cell count, absolute neutrophils count, serum C-reactive protein, and serum procalcitonin was analyzed.
RESULTS: A statistical difference was found in the mean value of sRAGE at PICU admission between patients and controls (1,215.7 ± 535 vs 849 ± 579 pg/ml). Also a significant inverse correlation was found between sRAGE and the Wood-Downes Score at admission (p = 0.02).
CONCLUSIONS: Serum sRAGE could be elevated in children with bronchiolitis. Larger clinical studies are necessary to elucidate its role as a bronchiolitis inflammatory and/or lung injury biomarker.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25355250     DOI: 10.1007/s00408-014-9663-9

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  25 in total

Review 1.  The immunobiology of the receptor of advanced glycation end-products: trends and challenges.

Authors:  Ileana González; Jacqueline Romero; Boris L Rodríguez; Ramón Pérez-Castro; Armando Rojas
Journal:  Immunobiology       Date:  2012-10-04       Impact factor: 3.144

2.  Association between serum levels of the soluble receptor (sRAGE) for advanced glycation endproducts (AGEs) and their receptor (RAGE) in peripheral blood mononuclear cells of children with type 1 diabetes mellitus.

Authors:  Athina Dettoraki; Andrea Paola Rojas Gil; Bessie E Spiliotis
Journal:  J Pediatr Endocrinol Metab       Date:  2009-10       Impact factor: 1.634

3.  Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients.

Authors:  Matthieu Jabaudon; Emmanuel Futier; Laurence Roszyk; Elodie Chalus; Renaud Guerin; Antoine Petit; Segolene Mrozek; Sebastien Perbet; Sophie Cayot-Constantin; Christian Chartier; Vincent Sapin; Jean-Etienne Bazin; Jean-Michel Constantin
Journal:  Crit Care Med       Date:  2011-03       Impact factor: 7.598

Review 4.  The receptor for advanced glycation end products (RAGE) and the lung.

Authors:  Stephen T Buckley; Carsten Ehrhardt
Journal:  J Biomed Biotechnol       Date:  2010-01-19

Review 5.  Soluble forms of RAGE in human diseases: clinical and therapeutical implications.

Authors:  Francesca Santilli; Natale Vazzana; Loredana G Bucciarelli; Giovanni Davì
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

Review 6.  Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Biochem Pharmacol       Date:  2010-01-22       Impact factor: 5.858

Review 7.  RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts.

Authors:  Ravichandran Ramasamy; Shi Fang Yan; Ann Marie Schmidt
Journal:  J Leukoc Biol       Date:  2009-05-28       Impact factor: 4.962

8.  RAGE and ICAM-1 differentially control leukocyte recruitment during acute inflammation in a stimulus-dependent manner.

Authors:  David Frommhold; Anna Kamphues; Susanne Dannenberg; Kirsten Buschmann; Victoria Zablotskaya; Raphaela Tschada; Baerbel Lange-Sperandio; Peter P Nawroth; Johannes Poeschl; Angelika Bierhaus; Markus Sperandio
Journal:  BMC Immunol       Date:  2011-10-04       Impact factor: 3.615

9.  A soluble receptor for advanced glycation end-products inhibits hypoxia/reoxygenation-induced apoptosis in rat cardiomyocytes via the mitochondrial pathway.

Authors:  Caixia Guo; Xiangjun Zeng; Juanjuan Song; Min Zhang; Hongxia Wang; Xiaowei Xu; Fenghe Du; Buxing Chen
Journal:  Int J Mol Sci       Date:  2012-09-20       Impact factor: 6.208

10.  Clinical risk factors are more relevant than respiratory viruses in predicting bronchiolitis severity.

Authors:  Silvia Ricart; Maria Angeles Marcos; Marta Sarda; Andres Anton; Carmen Muñoz-Almagro; Tomas Pumarola; Marti Pons; Juan Jose Garcia-Garcia
Journal:  Pediatr Pulmonol       Date:  2012-09-04
View more
  4 in total

1.  Use of procalcitonin and C-reactive protein in the diagnosis of bacterial infection in infants with severe bronchiolitis.

Authors:  Carme Alejandre; Carmina Guitart; Mònica Balaguer; Isabel Torrús; Sara Bobillo-Perez; Francisco José Cambra; Iolanda Jordan
Journal:  Eur J Pediatr       Date:  2020-09-14       Impact factor: 3.183

2.  Serum soluble receptor for advanced glycation end-products during acute bronchiolitis in infant: Prospective study in 93 cases.

Authors:  Carole Egron; Laurence Roszyk; Emmanuelle Rochette; Matthieu Jabaudon; Vincent Sapin; Aurélien Mulliez; André Labbé; Karen Coste
Journal:  Pediatr Pulmonol       Date:  2018-08-16

3.  Plasma Biomarker Analysis in Pediatric ARDS: Generating Future Framework from a Pilot Randomized Control Trial of Methylprednisolone: A Framework for Identifying Plasma Biomarkers Related to Clinical Outcomes in Pediatric ARDS.

Authors:  Dai Kimura; Jordy Saravia; Cynthia R Rovnaghi; Gianfranco Umberto Meduri; Andreas Schwingshackl; Stephania A Cormier; Kanwaljeet J Anand
Journal:  Front Pediatr       Date:  2016-03-31       Impact factor: 3.418

Review 4.  Biomarkers in Pediatric ARDS: Future Directions.

Authors:  Benjamin E Orwoll; Anil Sapru
Journal:  Front Pediatr       Date:  2016-06-01       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.